The North America patient controlled injectors market is expected to reach US$ 3,236.46 million by 2027 from US$ 1,261.43 million in 2019; it is expected to grow at a CAGR of 12.6% from 2020 to 2027. The increasing prevalence of chronic diseases and limitations on conventional drug delivery system boost the growth of the market.However, the preference of alternative drug delivery restrains the growth of the market.
Technological advancements and design development, and patient-controlled injector industries consolidation are likely to fuel the growth of the North America patient controlled injectors market during the forecast period. Patient controlled Injectors are subcutaneous drug delivery systems that adhere to the body and administer larger volumes (more than 2 mL) of a drug over an extended period.With the use of patient-controlled injectors, dosing errors, microbial contamination risks, and needle stick injuries can be avoided that are caused during parenteral drug administration using injections.
In the last few years, the pharmaceutical industry has witnessed the introduction of several innovative interventions for the treatment of various chronic diseases. Chronic diseases—such as blood disorder, autoimmune disorders, and various types of cancer—are the leading causes of death and disability.According to the Centers for Disease Control and Prevention (CDC), in 2019, nearly 6 in 10 people suffer from at least one chronic disease in the US.
Cardiovascular diseases (CVDs) are a significant cause of mortality owing to the hectic lifestyle.As per the CDC, 1 person dies every 36 seconds in the US from CVD.
Around 655,000 people in the US die from heart disease each year—that’s 1 in every 4 deaths.Many biologics are commercially available for the treatment, but the conventional drug delivery methods are unable to provide accurate dosage.
In this case, the use of patient controlled injector drug delivery systems plays vital role to provide targeted drug delivery and prolonged drug residence to the affected areas of the cardiovascular system. Hence, the adoption of patient controlled injectors is likely to increase. Moreover, there is an increase in the prevalence of autoimmune diseases such as plaque psoriasis, Addison disease, celiac disease - sprue (gluten-sensitive enteropathy), dermatomyositis, Graves’ disease, Hashimoto thyroiditis, multiple sclerosis, myasthenia gravis, and pernicious anemia.Thus, rising prevalence of diseases and need for easy administration have led the manufacturers to fulfill the unmet demand for the patient controlled injectors.
Above mentioned factors are leading to a rise in demand for patient controlled injectors, thereby boosting the growth of the market. North America is reporting continuously growing number of COVID-19 cases since its outbreak.According to Worldometer, as of November 13, 2020, the number of COVID-9 positive cases is 10,880,282 with 248,635 reported deaths in the US.
The cases are also increasing in Mexico and Canada.Several measures are being taken to contain the disease and prevent the transmission.
Patients with severe health conditions such as diabetes, immune diseases, cardiovascular, and cancer need physical distancing with others; however, delays in such chronic disease treatments are distressing. Therefore, it is restraining the North America patient controlled injectors market. In 2019, the electronic injector segment accounted for the largest market share of the North America patient controlled injectors market.Electronic injector offers various benefits such as comfort, water resistance, flexible dosing, and automatic warming of refrigerated drug as well as it is easy to use.
These benefits accelerate the demand for electronic injector. A mechanical injector eliminates the risks of skin fitting issues and allergic skin reactions; therefore, the market for mechanical injector segment is expected to grow at a faster pace during the forecast period. A few of the major secondary sources referred to while preparing this report on the North America patient controlled injectors market are the World Health Organization (WHO), Global Burden of Disease (GBD), Centers of Disease Control and Prevention (CDC), American Heart Association (AHA), and American Diabetes Association.
Our reports have been used by over 10K customers, including:
240 pages •
By Asia Market Information & Development Company
• Apr 2021
China’s demand for Genome-Based Drug has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption...
Quick care: Federal funding for Medicare and Medicaid will increase, boosting industry revenue Abstract Pharmacies & Drug Stores in Georgia Pharmacies and drug stores retail a range of prescription and over-the-counter medications, health and beauty items, toiletries and consumable goods directly to...
The North America Over the Counter (OTC) Drugs Market is anticipated to grow with a CAGR of 2.7%, during the forecast period.
The OTC drugs market is innovation-driven and relies on the advent of innovative drugs for different disease complexities and vary in their degree of intensity, and efficacy. The product innovations in OTC...
The mail order pharmacy market was valued at US$ 48,977 million in 2019 and is projected to reach US$ 166,384.85 million by 2027; it is expected to grow at a CAGR of 16.5% from 2020 to 2027. Increasing incidences of chronic diseases and increasing adoption of mail order pharmacy in healthcare sector are among the major factors fueling...
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Online Pharmacy Market Report
The global online pharmacy market by revenue is expected to grow at a CAGR of over 20% during the period 2019–2025.
The global online pharmacy market size is likely to cross revenues of over $131 billion...
Advancement in filling machine technology and growth in the manufacturing of lyophilized drugs are projected to drive the dual chamber syringe (DCS) filling machine market. The global installed base of dual chamber syringe (DCS) filling machine market size is projected to grow from USD 258 million in 2020 to USD 381 million by 2025, at...
The Europe Chronic Cough market is projected to reach US$ 2,881.55 million by 2027 from US$ 1,647.94 million in 2019; it is estimated to grow with a CAGR of 7.3% from 2020 to 2027. The growth of the chronic cough market is primarily attributed to rising incidences of chronic cough, growing product developments to treat chronic cough. More...
The Asia Pacific chronic cough market is projected to reach US$ 2,155.25 millionby2027 from US$1,136.66 million in 2019; it is estimated to grow with a CAGR of 8.4%from 2020 to 2027. The growth of the Asia Pacific chronic cough market is primarily attributed to the rising incidences of chronic cough among population and growing product...
The North American Chronic Cough market is projected to reach US$ 3,944.89 million by 2027 from US$ 2,118.42 million in 2019; it is estimated to grow with a CAGR of 8.1% from 2020 to 2027. The growth of the chronic cough market is primarily attributed to rising incidences of chronic cough, growing product developments to treat chronic cough....
The global chronic cough market is expected to reach US$ 9,854.8 million by 2027 from US$ 5,430.0 million in 2019; it is estimated to grow at a CAGR of 7.8% from 2020 to 2027. The market growth is attributed to the key factors such as increasing rising incidences of chronic cough and growing product developments to treat chronic cough. On...
Research And Development
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.